Rogaratinib (BAY1163877) in Chinese Patients
This study is planned to determine the safety and tolerability of rogaratinib in Chinese patients with fibroblast growth factor receptor (FGFR)-positive refractory, locally advanced, or metastatic solid tumors and to characterize the pharmacokinetics of rogaratinib in Chinese patients.
Neoplasms
DRUG: Rogaratinib (BAY1163877)
Frequency of Treatment-Emergent Adverse Events(TEAEs), 30 days after last dose of rogaratinib|Severity of Treatment-Emergent Adverse Events(TEAEs), 30 days after last dose of rogaratinib|Cmax: Maximum drug concentration in plasma after dose administration, Single dose, Cycle 1 Day 1 (each cycle is 21 days)|AUC(0-12): AUC from time zero to 12 hours p.a. after first-dose administration, Single dose, Cycle 1 Day 1 (each cycle is 21 days)|Cmax,md: Cmax after multiple dosing, Multiple dose, Cycle 1 Day 15 (each cycle is 21 days)|AUC(0-12)md: AUC(0-12) after multiple dosing, Multiple dose, Cycle 1 Day 15 (each cycle is 21 days)
Phosphate levels, Within 7-14 days after the last dose of rogaratinib|Response rate, Response rate is defined as the proportion of patients who have a best overall response rating of complete response (CR) and partial response (PR) that is achieved during treatment., Within 7-14 days after the last dose of rogaratinib
This study is planned to determine the safety and tolerability of rogaratinib in Chinese patients with fibroblast growth factor receptor (FGFR)-positive refractory, locally advanced, or metastatic solid tumors and to characterize the pharmacokinetics of rogaratinib in Chinese patients.